Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

98 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Androgen receptor signaling pathways as a target for breast cancer treatment.
Pietri E, Conteduca V, Andreis D, Massa I, Melegari E, Sarti S, Cecconetto L, Schirone A, Bravaccini S, Serra P, Fedeli A, Maltoni R, Amadori D, De Giorgi U, Rocca A. Pietri E, et al. Among authors: sarti s. Endocr Relat Cancer. 2016 Oct;23(10):R485-98. doi: 10.1530/ERC-16-0190. Epub 2016 Aug 15. Endocr Relat Cancer. 2016. PMID: 27528625 Review.
A phase IB dose-finding trial of liposomal doxorubicin in combination with capecitabine in patients with pretreated metastatic breast cancer.
Rocca A, Maltoni R, Passardi A, Massa I, Aquilina M, Ridolfi R, Ibrahim T, Cecconetto L, Sarti S, Pietri E, Nanni O, Amadori D. Rocca A, et al. Among authors: sarti s. Cancer Chemother Pharmacol. 2010 Apr;65(5):871-6. doi: 10.1007/s00280-009-1092-8. Epub 2009 Aug 20. Cancer Chemother Pharmacol. 2010. PMID: 19693503 Clinical Trial.
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study.
Guarneri V, Frassoldati A, Bottini A, Cagossi K, Bisagni G, Sarti S, Ravaioli A, Cavanna L, Giardina G, Musolino A, Untch M, Orlando L, Artioli F, Boni C, Generali DG, Serra P, Bagnalasta M, Marini L, Piacentini F, D'Amico R, Conte P. Guarneri V, et al. Among authors: sarti s. J Clin Oncol. 2012 Jun 1;30(16):1989-95. doi: 10.1200/JCO.2011.39.0823. Epub 2012 Apr 9. J Clin Oncol. 2012. PMID: 22493419 Clinical Trial.
Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.
Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, Sarti S, Cecconetto L, Pietri E, Ferrario C, Fedeli A, Faedi M, Nanni O, Frassineti GL, Amadori D, Rocca A. Farolfi A, et al. Among authors: sarti s. Heart. 2013 May;99(9):634-9. doi: 10.1136/heartjnl-2012-303151. Epub 2013 Jan 24. Heart. 2013. PMID: 23349345
Efficacy of endocrine therapy in relation to progesterone receptor and Ki67 expression in advanced breast cancer.
Rocca A, Farolfi A, Maltoni R, Carretta E, Melegari E, Ferrario C, Cecconetto L, Sarti S, Schirone A, Fedeli A, Andreis D, Pietri E, Ibrahim T, Montalto E, Amadori D. Rocca A, et al. Among authors: sarti s. Breast Cancer Res Treat. 2015 Jul;152(1):57-65. doi: 10.1007/s10549-015-3423-2. Epub 2015 May 27. Breast Cancer Res Treat. 2015. PMID: 26012644
Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer.
Guarneri V, Dieci MV, Frassoldati A, Maiorana A, Ficarra G, Bettelli S, Tagliafico E, Bicciato S, Generali DG, Cagossi K, Bisagni G, Sarti S, Musolino A, Ellis C, Crescenzo R, Conte P. Guarneri V, et al. Among authors: sarti s. Oncologist. 2015 Sep;20(9):1001-10. doi: 10.1634/theoncologist.2015-0138. Epub 2015 Aug 5. Oncologist. 2015. PMID: 26245675 Free PMC article. Clinical Trial.
Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.
Rocca A, Cecconetto L, Passardi A, Melegari E, Andreis D, Monti M, Maltoni R, Sarti S, Pietri E, Schirone A, Fabbri F, Donati C, Nanni O, Fedeli A, Faedi M, Amadori D. Rocca A, et al. Among authors: sarti s. Cancer Chemother Pharmacol. 2017 May;79(5):863-871. doi: 10.1007/s00280-017-3279-8. Epub 2017 Mar 24. Cancer Chemother Pharmacol. 2017. PMID: 28341957 Free PMC article. Clinical Trial.
98 results